Press Releases

LONDON, Jan. 5, 2018 /PRNewswire/ — Download the full report: https://www.reportbuyer.com/product/5262345

Digital transformation is a journey, but one that companies need to embark on if they are to survive not just the onslaught of traditional competition, but new market entrants. It is also a necessary component in keeping pace with the rapidly changing consumer base.
South Africa’s customer service delivery is predominantly dominated by the BPO market, specifically contact centers. The BPO sector contributes ZAR50 billion to towards the national GDP and employed 222,500 people in 2016. The domestic BPO market represents 85.4% of the market, and is the backbone for the development and expansion of the offshore BPO market.

Research Scope

The global technology trends that will be shaping the BPO market in South Africa are automation, data analytics, Internet of Things (IoT) Artificial Intelligence (AI). The focus of this research is to understand the global technological changes that will be affecting the way service is delivered to customers.

The study will focus on understanding the South African BPO market landscape, the changes in the BPO ecosystem as a result of innovative technologies, the key trends shaping customer experience management, and the growth opportunities and Companies to Action (C2A).

Research Highlights
While there are too many developing technology components to delve into in this insight, the following areas should be on the radar of any company starting on the digital transformation path.
Emergence of the Internet of Things (IoT): Companies need to investigate the impact that device connectivity, cloud computing, and advanced analytics can have on changing the customer experience.
Security: Companies need to keep abreast and plan for the ongoing security threats to digital assets.
Big Data: Big Data is moving beyond the realms of data projects and into enriching what companies know about customers.
Advanced Analytics: Companies are well advised to investigate how to make use of advancements in analytics. Understanding customer wants, needs, and behaviors and predicting outcomes is key to owning the customer experience. Areas to investigate include advancements in AI, machine learning, and speech and text analytics.
Virtual Assistants, Intelligent Personal Assistants, and Robotic Process Automation: Customers prefer to self-serve before contacting a business. Embellishing self-service options from the growing ranks of digital personal assistants can help differentiate and transform customer interaction.
Mobility: Companies need to meet customers where they live and that is on mobile devices.
Extending business access to the device of choice for the consumer is key to changing the customer experience and cementing brand loyalty.

Download the full report: https://www.reportbuyer.com/product/5262345

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com  

View original content:http://www.prnewswire.com/news-releases/south-african-bpo-market-2017-300578135.html

SOURCE ReportBuyer

SAN FRANCISCO, Jan. 5, 2018 /PRNewswire/ — Datavant, a company focused on organizing and structuring healthcare data to inform actionable insights for the design and interpretation of clinical trials, and Verge Genomics, a company using artificial intelligence to discover and develop new therapeutics, today announced a strategic alliance to unlock the value of pharmaceutical datasets to accelerate drug discovery and development.

Datasets with relevance to drug development are currently siloed and fragmented across pharmaceutical companies, payers, hospital systems, and many others. Datavant partners with a wide range of healthcare organizations to aggregate and integrate these datasets, with over 100 clinical datasets reflecting over 150 million unique patients integrated to date. This is complementary to Verge’s proprietary machine learning algorithms, drug discovery engine, and patient database. When combined, the collaboration aims to connect the full stack of data from early discovery to clinical development and apply machine learning to unlock dozens of breakthrough opportunities and insights for clinical trial design and interpretation.

This alliance marks the third innovative data partnership that Verge has struck in the last six months and its first expansion into the pharmaceutical data landscape. Since September, Verge has forged two innovative public-private partnerships across a dozen academic and national institutions, leading to the creation of one of the world’s largest collections of ALS and Parkinson’s Disease patient data.

Roivant Sciences, with the investment support of SoftBank Vision Fund and Founders Fund, spun out Datavant in September 2017 as an important part of its goal to reduce the time and cost of the drug development process.

“At Verge, we believe that breaking down the barriers that exist between industry, academia, computation and biology is critical to fully realizing the potential of AI in drug discovery,” said Alice Zhang, CEO of Verge Genomics. “Our partnership with Datavant advances this mission by opening up new data opportunities previously siloed within pharmaceutical companies.”

“Verge’s robust data and expertise in computational biology add tremendous value in contextualizing signals seen in clinical trials and providing a foundation for better trial designs. We are delighted to partner with Verge to accelerate the drug development process and get more treatments to the patients who need them,” said Travis May, President and Co-Founder of Datavant. 

About Datavant
Datavant is a technology company dedicated to organizing and integrating the world’s healthcare data. Datavant’s products improve the design and interpretation of clinical trials through data integration and artificial intelligence, increasing the odds of success of clinical trials and helping more drugs reach patients. Datavant’s vision is backed by Roivant Sciences, SoftBank Vision Fund, and Founders Fund and is located in San Francisco. For additional information, please visit http://www.datavant.com.

About Verge Genomics
Verge Genomics is a next-generation therapeutics company that is using human genomic data to accelerate drug discovery. Founded by scientists from leading neuro-genomics labs, the Verge team is 14 people including 12 Ph.D.’s in machine learning, neuroscience, applied math, biophysics, statistics, and computational biology from UCLA, Stanford, Oxford, UCSF, and the pharmaceutical sector. For additional information, please visit http://www.vergegenomics.com.

CONTACT: Lucia Huang, lucia@vergegenomics.com

 

 

View original content:http://www.prnewswire.com/news-releases/datavant-and-verge-genomics-forge-strategic-alliance-to-accelerate-drug-development-300578020.html

SOURCE Verge Genomics

LAS VEGAS, Jan. 5, 2018 /PRNewswire/ — Consumer Electronics Show — CEVA, Inc. (NASDAQ: CEVA), the leading licensor of signal processing platforms and artificial intelligence processors for smarter, connected devices, today unveiled NeuPro™, a powerful and specialized Artificial Intelligence (AI) processor family for deep learning inference at the edge. The NeuPro family of processors is designed for smart and connected edge device vendors looking for a streamlined way to quickly take advantage of the significant possibilities that deep neural network technologies offer.

NeuPro builds on CEVA’s industry-leading position and experience in deep neural networks for computer vision applications. Dozens of customers are already deploying the CEVA-XM4 and CEVA-XM6 vision platforms along with the CDNN neural network software framework in consumer, surveillance and ADAS products. This new family of dedicated AI processors offers a considerable step-up in performance, ranging from 2 Tera Ops Per Second (TOPS) for the entry-level processor to 12.5 TOPS for the most advanced configuration.

The NeuPro processor line extends the use of AI beyond machine vision to new edge-based applications including natural language processing, real-time translation, authentication, workflow management, and many other learning-based applications that make devices smarter and reduce human involvement.

Ilan Yona, vice president and general manager of the Vision Business Unit at CEVA, commented: “It’s abundantly clear that AI applications are trending toward processing at the edge, rather than relying on services from the cloud. The computational power required along with the low power constraints for edge processing, calls for specialized processors rather than using CPUs, GPUs or DSPs. We designed the NeuPro processors to reduce the high barriers-to-entry into the AI space in terms of both architecture and software. Our customers now have an optimized and cost-effective standard AI platform that can be utilized for a multitude of AI-based workloads and applications.”

The NeuPro architecture is composed of a combination of hardware-based and software-based engines coupled for a complete, scalable and expandable AI solution. Optimizations for power, performance, and area (PPA) are achieved using a precise mix of hardware, software and configurable performance options for each application tier.

The NeuPro family comprises four AI processors offering different levels of parallel processing:

• NP500 is the smallest processor, including 512 MAC units and targeting IoT, wearables and cameras
• NP1000 includes 1024 MAC units and targets mid-range smartphones, ADAS, industrial applications and AR/VR headsets
• NP2000 includes 2048 MAC units and targets high-end smartphones, surveillance, robots and drones
• NP4000 includes 4096 MAC units for high-performance edge processing in enterprise surveillance and autonomous driving

Each processor consists of the NeuPro engine and the NeuPro VPU. The NeuPro engine includes the hardwired implementation of neural network layers among which are convolutional, fully-connected, pooling, and activation. The NeuPro VPU is a cost-efficient programmable vector DSP, which handles the CDNN software and provides software-based support for new advances in AI workloads. NeuPro supports both 8-bit and 16-bit neural networks, with an optimized decision made in real time in order to deliver the best tradeoff between precision and performance. The MAC units achieve better than 90% utilization when running, ensuring highly optimized neural network performance. The overall processor design reduces DDR bandwidth substantially, improving power consumption levels for any AI application.

The NeuPro family, coupled with CDNN, CEVA’s award winning neural network software framework, provides the ultimate deep learning solution for developers to easily and efficiently generate and port their proprietary neural networks to the processor. CDNN supports the full gamut of layer types and network topologies, enabling fastest time-to-market.

In conjunction with the NeuPro processor line, CEVA will also offer the NeuPro hardware engine as a Convolutional Neural Network (CNN) accelerator. When combined with the CEVA-XM4 or CEVA-XM6 vision platforms, this provides a flexible option for customers seeking a single unified platform for imaging, computer vision and neural network workloads.

Availability
NeuPro will be available for licensing to select customers in the second quarter of 2018 and for general licensing in the third quarter of 2018.

For more information on the NeuPro family of processors, visit: https://www.ceva-dsp.com/product/ceva-neupro/.

CEVA at CES
CEVA executives and experts will be attending CES 2018, January 9-12, 2018. To schedule a meeting to discuss NeuPro or to experience and interact with the latest CEVA-powered smart and connected products and demos, e-mail sales@ceva-dsp.com.

About CEVA, Inc.
CEVA is the leading licensor of signal processing platforms and artificial intelligence processors for a smarter, connected world. We partner with semiconductor companies and OEMs worldwide to create power-efficient, intelligent and connected devices for a range of end markets, including mobile, consumer, automotive, industrial and IoT. Our ultra-low-power IPs for vision, audio, communications and connectivity include comprehensive DSP-based platforms for LTE/LTE-A/5G baseband processing in handsets, infrastructure and machine-to-machine devices, advanced imaging and computer vision for any camera-enabled device, audio/voice/speech and ultra-low power always-on/sensing applications for multiple IoT markets. For artificial intelligence, we offer a family of AI processors capable of handling the complete gamut of neural network workloads, on-device. For connectivity, we offer the industry’s most widely adopted IPs for Bluetooth (low energy and dual mode) and Wi-Fi (802.11 a/b/g/n/ac up to 4×4). Visit us at www.ceva-dsp.com and follow us on Twitter, YouTube and LinkedIn.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/ceva-unveils-neupro—a-family-of-ai-processors-for-deep-learning-at-the-edge-300577794.html

SOURCE CEVA, Inc.

NEW YORK, Jan. 5, 2018 /PRNewswire/ — Sumitomo Corporation of Americas (SCOA) announced today its investment in ActiveScaler Inc., a startup that develops Managed MaaS (Mobility-as-a-Service) systems powered by artificial intelligence, alongside DENSO, a leading global automotive components manufacturer, as well as other strategic investors. ActiveScaler will use the investment to continue development and deployment of its Managed MaaS system for leading mobility operators and fleet service providers.

“We want to be the engine behind the future of MaaS – hence the term “Managed MaaS”, which will transform current fleet businesses to provide next generation mobility services,” said Abhay Jain, CEO of ActiveScaler. “Traditional fleet management services and systems are quickly becoming obsolete because of issues like high upfront software and hardware costs, poor ecosystem integration, and lack of flexibility, which are limiting the type and quality of services that can be offered.”

With the increase in global demand for more scalable and efficient services for moving people and goods, ActiveScaler aims to be the leading provider of fully automated operations management for transportation businesses. We accelerate growth and simplify implementation with a modular set of components that enable mobility service providers to deploy solutions to meet their evolving business needs. ActiveScaler is working with a variety mobility providers offering services ranging from regional door-to-door plan, book and pay services with multiple transport modes, to comprehensive AI-based systems for managing fleets of autonomous vehicles and delivery trucks. 

“Our new technology and fresh approach provides the ability to build end-to-end MaaS businesses featuring advanced analytics and automation, high security, and regulatory compliance while reducing environmental impact. This is essential for current as well as future businesses built around multi-mode transportation and autonomous vehicles,” continued Abhay Jain, CEO of ActiveScaler.

“Sumitomo is a leader in global fleet management and supports its customers in efficiently transporting passenger and cargo from point A to point B, so we see real value in ActiveScaler’s technology platform,” said Sam Kato, Senior Vice President and General Manager of the Auto & Aerospace Group at SCOA.  “We believe this technology will aid the MaaS industry in optimizing fleet management efficiency and getting the best performance out of their vehicles. We look forward to supporting both ActiveScaler and the fleets by linking them together.”

Currently operating in Asia with over 400 fleets and 35,000 vehicles under management, ActiveScaler’s In-Motion™ platform is proven to be reliable and scalable while improving operational efficiency. Many types of fleets including taxi, limo, shuttles, busses, delivery and service vehicles and long-haul trucks are becoming part of the MaaS movement and making operational efficiency a priority.

The ActiveScaler founding team includes Abhay Jain CEO, Paul Gulati COO, Amit Jain CTO, and David Nagy CMO, bringing broad experience from companies like Apple, Cisco, Evernote, F5, Nuko, Seeing Machines, Verifone, and @Road.

About Sumitomo Corporation of Americas
Established in 1952 and headquartered in New York City, Sumitomo Corporation of Americas (SCOA) has 9 offices in major U.S. cities. SCOA is the largest subsidiary of Sumitomo Corporation, one of the world’s leading traders of goods and services. As an integrated business enterprise, the firm has emerged as a major organizer of multinational projects, an expediter of ideas, an important international investor and financier, and a powerful force for distribution of products and global communications through a network of offices worldwide. Its core business units include Tubular Products, Environment and Infrastructure, Steel and Non Ferrous Metals, Transportation and Construction Systems, Chemicals and Electronics, Media and IOT Applications, Real Estate, Mineral Resources and Energy, and Food. SCOA is an experienced leader in promoting advances in automobile manufacturing, and has provided technical innovations to aid U.S. enterprises like Ford, GM and Navistar. Its Transportation Unit provides total project management for its clients, including sourcing, logistics and installation of product equipment for leading manufacturers.   In collaboration with SCOA affiliate company, Presidio Ventures, an early stage investment firm headquartered in Silicon Valley for more than 20 years, SCOA is expanding its portfolio by incorporating new technologies emerging in the mobility space. For more information, visit www.sumitomocorp.com.

About ActiveScaler Inc.
ActiveScaler exponentially improves the flow of people and goods for transportation providers. The company’s Managed Mobility-as-a-Service (Managed MaaS) product suite includes FleetFactor™, In-Motion™ global platform and API, and IMBOT™ that revolutionize mobility by automating operations management with contextual analytics, machine learning and artificial intelligence. Transportation providers can readily improve and expand service offerings while making sense of a growing stream of real-time data. ActiveScaler focuses on serving a range of transportation providers from individual mobility operators to multi-mode integrators and large scale commercial fleets. For more information, please visit www.activescaler.com.

About DENSO Corporation
DENSO Corp., headquartered in Kariya, Aichi prefecture, Japan, is a leading global automotive supplier of advanced technology, systems and components in the areas of thermal, powertrain control, electronics and information and safety. Its customers include all the world’s major carmakers. Worldwide, the company has more than 200 subsidiaries and affiliates in 38 countries and regions (including Japan) and employs more than 150,000 people. Consolidated global sales for the fiscal year ending March 31, 2017, totaled US$40.4 billion. Last fiscal year, DENSO spent 9.0 percent of its global consolidated sales on research and development.

DENSO common stock is traded on the Tokyo and Nagoya stock exchanges. For more information, go to www.denso.com, or visit our media website at www.denso.com/global/en/news/media-center/.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/activescaler-closes-first-strategic-funding-led-by-denso-to-debut-managed-maas-300577814.html

SOURCE Sumitomo Corporation of Americas

SAN FRANCISCO, Jan. 5, 2018 /PRNewswire/ — Datavant, a healthcare technology company that aggregates and structures healthcare data to generate actionable insights for clinical trials, announced today that it has selected the Duke Clinical Research Institute (DCRI), the world’s largest academic clinical research organization, as an analytical partner to accelerate data-driven approaches in drug development.

As Datavant’s Founding Academic Partner, the DCRI will bring deep insights and unique perspectives on data-driven clinical research and access to clinical trial and health system data to augment Datavant’s analytical tools and data assets. The DCRI will gain early access to Datavant’s data and technology. Together, the organizations will create further opportunities to facilitate rapid scaling of best practices in clinical research to improve patient outcomes.

“New clinical insights come from matching the right question with data that can actually inform its answer,” said Michael J. Pencina, the DCRI’s Director of Biostatistics and a professor of biostatistics and bioinformatics at Duke School of Medicine. “The promise of this partnership comes from the blend of the DCRI’s analytic innovations with Datavant’s unique datasets, creating unmatched capacity for discovery.”

“Too many drugs fail clinical trials due to deficiencies in trial design and interpretation, depriving patients of new treatment options they desperately need. We believe that the combination of the DCRI’s analytical expertise and rich datasets combined with Datavant’s products and data hold the potential to be transformative for the industry,” said Travis May, President and Co-Founder of Datavant.

About DCRI
As the world’s largest academic research organization and part of the Duke University School of Medicine, the Duke Clinical Research Institute (DCRI) is known globally for conducting groundbreaking multinational trials, managing major national patient registries, and performing landmark research. We combine the faculty expertise of one of the most prestigious university medical centers with the full-service operational capabilities of a major contract research organization to fulfill our mission: to develop and share knowledge that improves the care of patients around the world through innovative clinical research.

About Datavant
Datavant is a San Francisco-based company dedicated to organizing the world’s healthcare data. Datavant’s products improve the design and interpretation of clinical trials through data integration and artificial intelligence, increasing the odds of success for clinical trials and helping more drugs reach patients.

Datavant’s vision is backed by Roivant Sciences, SoftBank Vision Fund, and Founders Fund.

Related Links
www.dcri.org  
www.datavant.com

Datavant Contact:
Sam Roosz; Head of Business Development & Partnerships
sam@datavant.com

View original content:http://www.prnewswire.com/news-releases/datavant-selects-the-duke-clinical-research-institute-as-founding-academic-partner-to-accelerate-innovation-in-data-driven-clinical-research-300578060.html

SOURCE Datavant

SAN FRANCISCO and ATLANTA, Jan. 5, 2018 /PRNewswire/ — Global Genomics Group (“G3”), a precision-medicine-based biopharmaceutical company that leverages large-scale genomic and molecular profiling to develop life-changing diagnostics and therapeutics, and Datavant, a healthcare technology company that aggregates and structures healthcare data to generate actionable insights for clinical trial design and interpretation, today announced a strategic partnership to improve the design and interpretation of clinical trials.

Through this partnership, Datavant and G3 will work together to increase the odds of success and pace of drug development through data-driven approaches. The partners will use G3’s proprietary platform and data from the G³LOBAL database, a panomic dataset characterizing disease networks and biomarkers in approximately 8,000 patients. The robust dataset includes whole-genome sequencing, whole-transcriptome sequencing, proteomics, lipodomics, lipoprotein proteomics, and quantitative precision imaging data. Together with Datavant’s Clinical Trial Data Cloud, a longitudinal combination of real-world evidence and clinical trial data, and advanced analytics, the partners expect to create new models for developing trial enrollment criteria, endpoints, and contextualizing trial results.

“We are delighted to work with Datavant to improve pharmaceutical clinical trial design and interpretation. The traditional model of drug development and clinical trial programs is no longer sustainable, and we believe that the combination of biological Big Data, together with sophisticated analytical tools, such as artificial intelligence and machine learning, are essential to turning around the pharmaceutical industry and drug development. We see Datavant at a very important intersection of cutting-edge analytical sciences and life sciences and we are looking forward to working together,” said Szilard Voros, Founder and CEO of G3.

“The key to success for a clinical trial often rests in identifying the right patients to enroll or in identifying biomarkers for efficacy/safety as early as possible in development. To that end, we’re excited to partner with G3 and gain access to both their deep domain expertise and robust panomic datasets to support the development strategies of our biopharmaceutical clients,” said Travis May, President and Co-Founder of Datavant.

About G3
G3 is the leading precision-medicine-based biopharmaceutical company, developing genetically validated drug targets and novel biomarkers based on biological Big Data, using novel artificial intelligence and machine-learning algorithms and traditional systems-biology-driven bioinformatics approaches to unravel new biologies of common, chronic diseases and rare diseases. G3 combines precision phenotyping with pan-omics (genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics and lipoprotein proteomics) and systems-biology driven bioinformatics to investigate the development and progression of common chronic diseases, as well as rare and orphan diseases.

For additional information, please visit www.globalgenomicsgroup.com

About Datavant
Datavant is a San Francisco-based company dedicated to organizing the world’s healthcare data. Datavant’s products improve the design and interpretation of clinical trials through data integration and artificial intelligence, increasing the odds of success for clinical trials and helping more drugs reach patients.

Datavant’s vision is backed by Roivant Sciences, SoftBank Vision Fund, and Founders Fund.

Related Links
www.globalgenomicsgroup.com
www.datavant.com  

G3 Contact:
Brad Brown; VP of Clinical Affairs
brad.brown@globalgenomicsgroup.com

Datavant Contact:
Sam Roosz; Head of Business Development & Partnerships
sam@datavant.com

View original content:http://www.prnewswire.com/news-releases/global-genomics-group-and-datavant-announce-strategic-partnership-to-improve-design-and-interpretation-of-clinical-trials-300578061.html

SOURCE Datavant

SAN FRANCISCO, Jan. 5, 2018 /PRNewswire/ — Datavant, a healthcare technology company that organizes the world’s healthcare data, today announced the integration of its 150th dataset, and named the Duke Clinical Research Institute (DCRI) as its Founding Academic Partner.

In the three months since its launch, Datavant has sourced and integrated 150 datasets, incorporating a diverse range of data types including pharmaceutical clinical trial data, claims data, pharmacy data, electronic health records, and genomics, among others. Datavant is forging strategic partnerships with leading pharmaceutical companies, payers, providers, and analytics companies to build an ecosystem of data that represents over 150 million unique patients, and includes detailed clinical trial outcomes from over 33,000 trials. This data is being used to improve clinical trial design and interpretation with the aim of ultimately bringing more medicines to market for patients.

“We’re delighted to have developed such a strong set of foundational partnerships since launching Datavant,” said Travis May. “Healthcare data is extremely siloed today, and we aspire to organize it to accomplish our goal of doubling the success rate of drugs entering clinical trials by 2020.”

In addition to its sustained momentum acquiring and integrating datasets, Datavant has assembled a leading team of technology and healthcare experts, including:

• President and Co-Founder Travis May, who was previously Co-Founder and CEO of LiveRamp, a marketing technology company he grew to over $200 million in revenue (acquired by Acxiom)
• Chief Scientific Officer Eric Perakslis, former CIO and Chief Scientist at the FDA and SVP of Bioinformatics at Takeda
• Head of Pharmaceutical Solutions Kailash Swarna, a former Associate Partner at IBM Global Business Services and Watson Health
• Head of Engineering and Data Science Aneesh Kulkarni, a former data science leader at Lyft

“We’re excited to work with Datavant to harness its datasets to answer important questions that improve patient outcomes,” said Michael J. Pencina, the DCRI’s Director of Biostatistics and a professor of biostatistics and bioinformatics at Duke School of Medicine. For more on the partnership with the DCRI, click here.

“Datavant is helping lead the change that is necessary for higher quality care for patients and a more effective healthcare system – through the collective power of data. This is uniquely aligned with Verge’s strategy of harnessing the power of genomic data in research and development,” said Alice Zhang, CEO of Verge Genomics. For more on the partnership with Verge Genomics, click here.

“At G3, we assembled one largest and most comprehensive biological Big Datasets, including whole genome sequencing, other ‘omics’ technologies, coupled with quantitative precision imaging. Datavant is the leading company at the intersection of life sciences and big-data analytics, and we are excited about the partnerships created under this umbrella,” said Szilard Voros, Founder and CEO of Global Genomics Group (“G3”). “We look forward to working with Datavant and its network of partners to develop new insights and translate them into better cures and better preventive measures for our patients.” For more on the partnership with G3, click here.

“At Mendel, we have aggregated hundreds of thousands of patients’ medical records and built AI tools that can analyze this data,” said Karim Galil, Founder and CEO of Mendel Health. “Integrating our data and technology with Datavant’s repository of data is a huge added value and we are looking forward to seeing the healthcare community reaping the benefits of organizing the world’s healthcare data through similar partnerships.”

About Datavant

Datavant is a San Francisco-based company dedicated to organizing the world’s healthcare data. Datavant’s products improve the design and interpretation of clinical trials through data integration and artificial intelligence, increasing the odds of success for clinical trials and helping more drugs reach patients.

Datavant’s vision is backed by Roivant Sciences, SoftBank Vision Fund, and Founders Fund.

Related Links
www.datavant.com

Datavant Contact:
Sam Roosz
sam@datavant.com  
+1 (765) 490-9385

View original content:http://www.prnewswire.com/news-releases/datavant-integrates-150th-data-source-and-announces-academic-partnership-with-duke-300578054.html

SOURCE Datavant

KARIYA, Japan, Jan. 5, 2018 /PRNewswire/ — DENSO, one of the world’s largest automotive suppliers, announced a significant investment in startup company ActiveScaler, a developer of Managed MaaS (Mobility-as-a-Service) systems powered by artificial intelligence. DENSO’s investment will help expand ActiveScaler’s platform and technologies, which simplify and better customize shared mobility experiences. The agreement also will help accelerate deployment of Managed MaaS systems for leading mobility operators and fleet service providers.

With the increase in global demand for more scalable and efficient services for moving people and goods, ActiveScaler’s technology will help enhance growth and simplify implementation with a modular set of components that enable mobility service providers and fleet managers to tailor MaaS solutions to their specific business needs.

“DENSO’s focus is to develop technologies that advance the future of mobility, and enable connected and automated driving,” said Yoshifumi Kato, Senior Executive Director at DENSO Corporation. “These technologies directly influence the development of MaaS systems, which will disrupt the future of urban mobility for people and goods by making transportation solutions more seamless and accessible. ActiveScaler will help fleet operators accelerate new business opportunities by integrating the emerging MaaS ecosystem with higher performance and faster time to market.”

Tony Cannestra, Director of Corporate Ventures for DENSO, emphasized the importance of collaboration for innovative technology development. “Technologies that simplify and better customize shared mobility experiences are a key focus area for DENSO, and we will strongly support those technologies with strategic investments and boundary-pushing collaborations,” said Cannestra. “ActiveScaler’s robust platform has the potential to impact how commercial fleets navigate city streets around the world, and we look forward to seeing how our technologies can help.”

“We want to be the engine behind the future of MaaS – hence the term “Managed MaaS,” which will transform current fleet businesses to provide next generation mobility services,” said Abhay Jain, CEO of ActiveScaler. “Traditional fleet management services and systems are quickly becoming obsolete because of issues like high upfront software and hardware costs, poor ecosystem integration, and lack of flexibility, which are limiting the type and quality of services that can be offered. 

“Our new AI-powered technology and fresh approach provides the ability to build end-to-end MaaS businesses featuring advanced analytics and automation, high security, and regulatory compliance while reducing environmental impact. This is essential for current as well as future businesses built around multi-mode transportation and autonomous vehicles,” added Jain.

DENSO continues to evaluate technology investment opportunities, including both core automotive solutions and innovative technologies with potentially significant implications for the future of transportation.

Opportunity for Startups at CES 2018
DENSO plans to expand its venture capital investments in a broad range of new technologies to make a world of self-driving, truly connected cars a reality. Startups attending CES can sign-up for a 20-minute pitch meeting by visiting www.densomedia-na.com/cesstartups. Meetings will take place on Wednesday, January 10 and Thursday, January 11 from 1-4pm PST at DENSO’s CES exhibit in LVCC, North Hall #7917.

About DENSO in North America
DENSO is a leading global automotive supplier of advanced technology, systems and components in the areas of thermal, powertrain control, electronics and information and safety. With its North American headquarters located in Southfield, Michigan, DENSO employs more than 23,000 people at 30 consolidated companies and affiliates across the North American region. Of these, 28 are manufacturing facilities located in the United States, Canada and Mexico. In the United States alone, DENSO employs more than 17,000 people in Alabama, Arkansas, California, Iowa, Georgia, Kentucky, Michigan, North Carolina, Ohio, Pennsylvania, South Carolina, Tennessee and Texas. DENSO’s North American consolidated sales totaled US$9.6 billion for the fiscal year ending March 31, 2017. For more information, go to www.denso.com/us-ca/en. Connect with DENSO on Facebook at www.facebook.com/DENSOinNorthAmerica.

About DENSO Corporation
DENSO Corp., headquartered in Kariya, Aichi prefecture, Japan, is a leading global automotive supplier of advanced technology, systems and components in the areas of thermal, powertrain control, electronics and information and safety. Its customers include all the world’s major carmakers. Worldwide, the company has more than 200 subsidiaries and affiliates in 38 countries and regions (including Japan) and employs more than 150,000 people. Consolidated global sales for the fiscal year ending March 31, 2017, totaled US$40.4 billion. Last fiscal year, DENSO spent 9.0 percent of its global consolidated sales on research and development. DENSO common stock is traded on the Tokyo and Nagoya stock exchanges. For more information, go to www.denso.com, or visit our media website at www.denso.com/global/en/news/media-center/

About ActiveScaler Inc.
ActiveScaler exponentially improves the flow of people and goods for transportation providers. The company’s Managed Mobility-as-a-Service (Managed MaaS) product suite includes FleetFactor™, In-Motion™ global platform and API, and IMBOT™ that revolutionize mobility by automating operations management with contextual analytics, machine learning and artificial intelligence. Transportation providers can readily improve and expand service offerings while making sense of a growing stream of real-time data. ActiveScaler focuses on serving a range of transportation providers from individual mobility operators to multi-mode integrators and large scale commercial fleets. For more information, please visit www.activescaler.com.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/denso-leads-ai-powered-fleet-management-technology-company-activescalers-seed-funding-round-300577980.html

SOURCE DENSO

DUBLIN, Jan. 5, 2018 /PRNewswire/ –

The “Artificial Intelligence and Robotics in Consumer, Enterprise, and Industrial Markets 2017 – 2022” report has been added to Research and Markets’ offering.

Artificial Intelligence is increasingly integrated in many areas including Internet search, entertainment, commerce applications, content optimization, and robotics. The long-term prospect for these technologies is that they will become embedded in many different other technologies and provide autonomous decision making on behalf of humans, both directly, and indirectly through many processes, products, and services. Leading industry verticals are beginning to see improved operational efficiency through the intelligent combination of AI and Robotics.

Personal robotics is anticipated to accelerate as consumer acceptance will increase substantially over the next five years. Robotics in business will accelerate as less expensive hardware and improvements in AI lead to improved cost structures and increased integration with enterprise software systems respectively. The massive amount of data generated by robotics will create opportunities for data analytics and AI-enabled decision support systems. Emerging areas for enterprise robotics include Robotics as a Service, Cloud Robotics, and General Purpose Robotics.

This comprehensive research offering addresses AI and Robotics in Consumer, Enterprise, and Industrial markets consisting of the following reports:

• Personal Artificial Intelligence and Robotics Market Outlook and Forecasts 2017 – 2022
• Aerial Drones in Industry and Defense: Market Outlook and Forecasts for UAV 2017 – 2025
• Robotics in Industrial, Enterprise, Military, and Consumer Products, Services, and Solutions 2017 – 2022
• Chatbots and Artificial Intelligence: Market Assessment, Application Analysis, and Forecasts 2017 – 2022
• Cloud Robotics: Technologies, Leading Companies, Solutions, Market Outlook, and Forecasts 2017 – 2022
• United States Enterprise Automation and Robotics: Market Analysis and Forecasts by Application 2017 – 2022
• Artificial Intelligence in Big Data Analytics and IoT: Market for Data Capture, Information and Decision Support Services 2017 – 2022
• Artificial Intelligence and Cognitive Computing: Market Outlook for Communications, Applications, Content, and Commerce 2017 – 2022

Target Audience:

• AI companies
• Robotics companies
• Investment organizations
• Data management vendors
• Industrial automation companies
• Enterprise across all industry verticals

Companies Mentioned

• 24me
• 2G Engineering
• 3D Robotics
• 5 Elements Robotics
• ABB Robotics
• Adept Technology Inc.
• Aethon Inc.
• Aido
• AIVC
• AlchemyAPI
• Alfred
• Alphabet, Inc. (Google)
• Amazon Robotics
• Blue Ocean Robotics ApS
• Branto
• Buddy
• C-B4
• Calvary Robotics
• Canvas Technology
• Carbon Robotics
• Carbon3D
• Celera Motion
• Charlie
• CISCO Systems Inc.
• Clara Labs
• Clearpath Robotics
• CloudMinds
• Comau Robotics
• Comfy
• Construction Robotics
• Creative Virtual Ltd.
• Cubic
• CX Company
• Cyberdyne
• Cyphy Works
• Daihen Corp.
• Delphi Automotive
• Denso Wave Inc.
• Diffbot
• Discovery Robotics
• DJI
• Dongbu Group
• EasilyDo
• Ecovacs Robotics, Inc.
• eGain Corporation
• Eidoserve Inc.
• Ekso Bionics
• Ellison Technologies Inc.
• Energid Technologies
• Erle Robotics
• EVA
• Evi
• Existor
• F&P Robotics AG
• GreyOrange
• H2O.ai
• Hanson Robotics Ltd.
• Happiest Minds Technologies
• Haptik, Inc.
• Hasbro, Inc.
• Helpshift
• Hoaloha Robotics
• Honda Motor Co. Ltd.
• HotBlack Robotics Srl
• Hound
• Hypertherm Inc.
• Iam Robotics
• IBM Watson
• iDAvatars (IDA)
• imagimob
• Indigo
• Infineon Technologies AG
• Intel Corporation
• InteliWISE SA
• Intuitive Surgical, Inc.
• inVia Robotics
• iRobot Corporation
• Jibo
• Kairos Autonomi
• Kawasaki
• Knightscope
• Kraken Sonar Systems Inc.
• KUKA AG
• Kuka Robotics
• Lego Education
• Lely Group
• Lockheed Martin
• Locus Robotics
• MAANA
• Matrix Industrial Automation
• Mazor Robotics
• McAfee
• Micromo
• Microsoft Corporation
• Milvus Robotics
• Mitsubishi Electric Corp.
• MJI Robotics
• MoBagel
• Mobile Industrial Robots ApS
• Modbot Inc.
• moov
• Motion Controls Robotics Inc.
• motion.ai
• Mycroft
• Nachi Fujikoshi Corp.
• Neato Robotics, Inc.
• NEURA
• NTT DoCoMo
• NVIDIA Corporation
• Octopuz Inc.
• Omnicell Inc.
• Open Bionics
• OpenAI
• Operator
• Ortelio Ltd
• Ozobot & Evollve Inc.
• Pari Robotics
• Parrot SA
• PointGrab Ltd.
• Precisionhawk
• PredictionIO
• Pv-Kraftwerker
• Qihan Technology Co.
• Rapyuta Robotics Co. Ltd.
• RealDoll
• ReconRobotics Inc.
• Reis Robotics
• Rewalk Robotics
• Robin
• Roboplan
• Robosoft Services Robots
• Robotbase
• Robotlab Inc.
• Rockwell Automation Inc.
• Rokid Inc.
• Samsung Electronics Co Ltd.
• Sapientx Inc.
• Savioke
• Schunk
• Seegrid
• Segway Inc.
• Sentenai Inc.
• Sentrian
• Seven Dreamers Laboratories Inc.
• Sharp Electronics Corp.
• Siasun Robot and Automation Co Ltd.
• Siemens
• SIRIUS
• SK Telecom Co, Ltd.
• Skype
• Skyspecs
• Soft Robotics Inc.
• SoftBank Robotics Holding Corp.
• Softweb Solutions Inc.
• Soil Machine Dynamics Ltd.
• Sony Corporation
• Spacex
• SparkCognition Inc.
• Speaktoit Inc.
• Sri International
• SSI Schaefer
• Starship Technologies
• Staubli International AG
• Stryker (Mako Surgical)
• Stubli
• Suitable Technologies
• Swisslog
• Syntouch
• Tachyus
• Tech-Con Automation Inc.
• Tellmeplus
• Tend.ai
• Teradyne Inc.
• Teun
• Titan Medical
• Tm Robotics
• Torc Robotics
• Touch Bionics
• Toyota
• Toyota Motor Corporation
• Transcend Robotics
• True Companion
• Twilio
• Twitter Inc.
• Ulc Robotics Inc.
• Universal Robots A/S
• Vecna Technologies
• Verb Surgical
• Veros Systems Inc.
• Vigilant Robots
• Vinclu Gatebox
• Virtual Incision Corporation
• Visual Components Oy
• Vokul
• WaveBot
• Willrich Precision Instrument Co.
• Wit.ai
• Wolf Robotics LLC
• World Drone Academy
• WowWee Group Limited
• Wunderlist
• Wynright (Daifuku Co Ltd)
• Yahoo Inc.
• Yaskawa Electric Corporation
• Yaskawa Motoman
• ZenRobotics
• ZMP INC.

For more information about this report visit https://www.researchandmarkets.com/research/fp5d2d/artificial?w=5

About Research and Markets
Research and Markets is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/artificial-intelligence-and-robotics-in-consumer-enterprise-and-industrial-markets—-forecasts-to-2022-300578107.html

SOURCE Research and Markets

HONG KONG and SHANGHAI, Jan. 5, 2018 /PRNewswire/ — Lung Nodule Analysis (“LUNA”), an internationally acclaimed assessment on the medical imaging field, released its evaluation results recently. It showed that the smart reading technology developed by Ping An Technology, a subsidiary of Ping An Insurance (Group) Company of China, Ltd. (hereafter “Ping An” or “the Group”, HKEx: 2318; SSE: 601318)’s has achieved major breakthroughs. It has refreshed the world records of “nodule detection” and “false positive reduction” with the respective accuracy of 95.1% and 96.8%, which both are ranked first in the world. This is the first time that Ping An Technology has won a world record in the medical imaging field and it is also a monumental achievement of the Group in the AI field.

LUNA official website screenshots:

 

The LUNA (Lung Nodule Analysis) evaluation is an international authoritative assessment on lung nodule detection. Since 2016, domestic and foreign professionals from academia and industry, including Chinese University of Hong Kong, Peking University, Alibaba and iFLYTEK have been actively participate in this evaluation. It has one of the most representative and most focused evaluation tasks in the medical imaging field. It is known that it uses data that is mainly from a number of medical institutions in the United States and jointly marked and completed by a number of medical experts.

As we know, Lung cancer is one of the cancers with the highest mortality in the world. At the present, the most suitable method, promoted by experts in the United States, is to have low-dose CT scan for the high-risk individuals for lung cancer. However, in the general screening process, doctors need to analyze millions of CT images, which causes a great burden for the treatment process. Therefore, the need for the development of smart lung cancer detection algorithm to optimize screening process becomes very urgent.

In response to this challenge, the medical imaging team of Ping An Technology, with its comprehensive knowledge in medical diagnosis field, creatively put forward the solution of integrating the theory of Robust Control with the advanced artificial intelligence algorithms such as deep learning and transfer learning. The result is a sound breakthrough in the area of lung nodule detection, location and identification. At the present, the technology is gradually being applied in actual computer-aided medical diagnosis scenarios in a number of top AAA hospitals.

It is reported that Ping An Technology’s artificial intelligence technology can also be used in gastric cancer detection, liver cancer recognition, bone age prediction, diabetic retinopathy screening and imaging-aided diagnosis for other diseases. In addition, in the medical treatment field, Ping An Technology also forms a high-precision OCR recognition algorithm through mass data training to complete the entry of transcribing text in images into digital data with the assistance of crowdsourcing operation for manual audit of the OCR results. This results in advancing the digital management of medical files. At the same time, smart medical procedures such as “face recognition for medical treatment” and “face recognition for payment” have greatly facilitated patient visits and enhanced the services and efficiencies of the public health care system.

In the AI prediction area, Ping An Technology, together with Chongqing CDC, has created the first disease prediction and screening model with “Artificial Intelligence + Big Data” in China to predict the occurrences of infectious diseases one week in advance and to help governments enhance efficiency, strengthen disease prevention and control costs in the prevention and control of related diseases.

Over the past 10 years, Ping An has invested more than RMB 50 billion in the research, development and application of innovative technologies and made major breakthroughs in the five core technologies (biometrics, big data, artificial intelligence, blockchain and cloud platform). At the present, its biometric technology is leading the world with the accuracy of 99.8% in face recognition, which has been used in 200+ scenarios and 800 million person-times. The accuracy in voiceprint recognition is over 99%, with a database of 50+ million voiceprints. The speed in micro-facial expression recognition is 1 second within 54 different complex micro-expressions.

Ping An believes that the new LUNA record set by this smart reading technology indicates that some of the technological innovations in AI technology created by Ping An Technology have shown their leads in the international scientific field. The Company will continue to push forward its two-pronged strategy of “Finance + Technology”. Through technology-driven innovations in the financial and healthcare industries, it will continue to cultivate and enhance the application of artificial intelligence technologies in multiple scenes and to implement technological achievements in its traditional financial services. While this strategy is enhancing its competitiveness, Ping An will also build an ecosystem and a platform to continually create innovative technologies to be the world’s leading fintech company.

For more information contact:

Vicky Cheng
+86-186-1706-3169
CHENGJING572@pingan.com.cn

View original content with multimedia:http://www.prnewswire.com/news-releases/ping-ans-lung-nodule-smart-reading-technology-is-evaluated-by-luna-as-no-1-in-the-world-300578105.html

SOURCE Ping An Insurance (Group) Company of China, Ltd.